Trial Profile
EVALUATING THE MORPHOFUNCTIONAL EFFECTS OF ECULIZUMAB THERAPY IN PRIMARY MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS: A PILOT, SINGLE ARM STUDY IN TEN PATIENTS WITH PERSISTENT HEAVY PROTEINURIA
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Eculizumab (Primary)
- Indications Membranoproliferative glomerulonephritis
- Focus Therapeutic Use
- Acronyms EAGLE
- 15 Jan 2018 Status changed from active, no longer recruiting to completed.
- 18 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
- 29 May 2017 Planned End Date changed from 1 Jun 2017 to 1 Dec 2017.